Bosutinib

7 trials 2 recruiting LOncology

Filter these 7 trials by condition, phase, country and more.

Open in Search →

7 Registered trials

2 Recruiting

5 Completed trials

6 Sponsors

19 Countries

Phase III

Phase II

Phase I/II

Phase III/IV

Phase III: 4 Phase II: 1 Phase I/II: 1 Phase III/IV: 1

Oversight events:

1 serious breach across 1 trial

View oversight register →

Indications tested

Chronic myeloid leukaemia 1

Sponsors using this IMP

Novartis Pharma AG 2 Ascentage Pharma Group Inc. 1 Centre Hospitalier Universitaire De Nantes 1 Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC) 1 Radboud universitair medisch centrum Stichting 1 St. Olavs Hospital HF 1

All trials

7 total

A Worldwide Study Testing the New Drug Olverembatinib for Patients with Chronic Phase Chronic Myeloid Leukemia (POLARIS-2) Recruiting

2024-511495-32-00 Phase III 6 countries Ascentage Pharma Group Inc.
Asciminib Roll-over Study Recruiting

2023-507557-16-00 Phase III 14 countries Novartis Pharma AG
A Patient guided dose reduction strategy of tyrosine kinase inhibitors in chronic myeloid leukaemia: RODEO study Ended

2024-516511-24-00 Phase III/IV 1 country Stichting Radboud universitair medisch centrum
AITIK-Discontinuation of TyrosIne Kinase Inhibitors (TKI) in Chronic Myeloid Leukemia (CML) and Impact on the Immune System Ended

2024-515479-36-00 Phase III 1 country Centre Hospitalier Universitaire De Poitiers
A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP Ended

2023-508838-33-00 Phase III 15 countries Novartis Pharma AG
A STUDY OF EFFICACY AND SAFETY OF LONG-ACTING LOW DOSE ROPEGINTERFERON IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA TREATED WITH BOSUTINIB FROM… Ended

2024-517417-32-00 Phase II 4 countries St. Olavs Hospital HF
Bosutinib in pediatric CML patients Ended

2023-504311-32-00 Phase I/II 5 countries Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)

Showing 1–7 of 7 trials

← All drugs A–Z